Bernhardt G. Zeiher, Director at Entrada Therapeutics, Inc. (TRDA), bought 5,000 shares at $5.86 ($29K) on 2026-05-20, disclosed to the SEC on 2026-05-21.
Director Bernhardt G. Zeiher purchased 5,000 shares of Entrada Therapeutics for $29,316 at $5.86, marking the largest insider purchase in the company's history. This move comes as the stock has crashed over 50% from its 52-week high, potentially signaling a contrarian bet on the company's DMD pipeline.
TRDA is down 51.72% over the last 30 days and 44.11% over the last 90 days, trading at $6.31, which is 61.59% below its 52-week high of $16.43.
1) Q2 earnings on August 5, 2026, following a +12.93% earnings surprise and +2.05% revenue beat in the prior quarter; 2) Continued data readouts from the Phase I/II ELEVATE-44-201 DMD trial, with initial safety and functional gains reported on May 9, 2026; 3) The largest insider purchase in company history, with 0 consecutive sells prior to this trade.
1) The stock dropped over 50% in May 2026 following disappointing efficacy data from the ENTR-601-44 DMD trial; 2) The company reported a Q1 loss of -86.24% on revenue misses in May 2026.
Clearly above the average filing.